Prise en charge du cancer rénal métastatique

Progrès en Urologie - Tập 18 - Trang S298-S308 - 2008
A. Méjean1,2, T. Lebret3
1Service d’Urologie, Université Paris Descartes
2Service d’Urologie, Assistance Publique – Hôpitaux de Paris, Hôpital Necker
3Service d’Urologie, Hôpital Foch, Faculté de médecine Paris-Île-de-France-Ouest, UVSQ

Tài liệu tham khảo

Zisman, 2002, Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma, J Clin Oncol, 20, 4559, 10.1200/JCO.2002.05.111

Raj, 2008, Preoperative nomogram predicting 12-year probability of metastatic renal cancer, J Urol, 179, 2146, 10.1016/j.juro.2008.01.101

Eggener, 2006, Renal cell carcinoma recurrence after nephrectomy for localized disease:predicting survival from time of recurrence, J Clin Oncol, 24, 3101, 10.1200/JCO.2005.04.8280

Jemal, 2007, Cancer statistics 2007, CA Cancer J Clin, 57, 43, 10.3322/canjclin.57.1.43

Patard, 2004, The changing evolution of renal tumours: a single center experience over a two-decade period, Eur Urol, 45, 490, 10.1016/j.eururo.2003.12.015

Janzen, 2003, Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease, Urol Clin North Am, 30, 843, 10.1016/S0094-0143(03)00056-9

Antonelli, 2007, The follow-up management of non-metastatic renal cell carcinoma:definition of a surveillance protocol, BJU Int, 99, 296, 10.1111/j.1464-410X.2006.06616.x

Hoffmann, 2008, Differences in organ system of distant metastasis by renal cell carcinoma subtype, J Urol, 179, 474, 10.1016/j.juro.2007.09.036

Motzer, 2007, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma, N Engl J Med, 356, 115, 10.1056/NEJMoa065044

Escudier, 2007, Sorafenib in advanced clear-cell renal-cell carcinoma, N Engl J Med, 356, 125, 10.1056/NEJMoa060655

Escudier, 2007, AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial, Lancet, 370, 2103, 10.1016/S0140-6736(07)61904-7

Motzer, 2008, Efficacy of everolimus in advanced renal cell carcinoma:a double-blind, randomised, placebo-controlled phase III trial, Lancet, 372, 449, 10.1016/S0140-6736(08)61039-9

Doublet, 2004, Le sous-comité rein. Adrenal gland tumors, Prog Urol, 14, 1039

Siemer, 2004, Adrenal metastases in 1635 patients with renal cell carcinoma: outcome and indication for adrenalectomy, J Urol, 171, 2155, 10.1097/01.ju.0000125340.84492.a7

Motzer, 1999, Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma, J Clin Oncol, 17, 2530, 10.1200/JCO.1999.17.8.2530

Motzer, 2002, Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma, J Clin Oncol, 20, 289, 10.1200/JCO.20.1.289

Négrier, 2002, Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d’Immunothérapie, Ann Oncol, 13, 1460, 10.1093/annonc/mdf257

Raj, 2008, Preoperative nomogram predicting 12-year probability of metastatic renal cancer, J Urol, 179, 2146, 10.1016/j.juro.2008.01.101

Herold, 1996, Lung metastases, Eur Radiol, 6, 596, 10.1007/BF00187656

Mejean, 2007, Kidney tumors, Prog Urol, 17, 1101, 10.1016/S1166-7087(07)74782-6

Shvarts, 2004, Eastern Cooperative Oncology Group performance status predicts bone metastasis in patients presenting with renal cell carcinoma: implication for preoperative bone scans, J Urol, 172, 867, 10.1097/01.ju.0000135803.91207.b0

Sellner, 2006, Solitary and multiple isolated metastases of clear cell renal carcinoma to the pancreas: an indication for pancreatic surgery, Ann Surg Oncol, 13, 75, 10.1245/ASO.2006.03.064

Kavolius, 1998, Resection of metastatic renal cell carcinoma, J Clin Oncol, 16, 2261, 10.1200/JCO.1998.16.6.2261

Kierney, 1994, Surgeon's role in the management of solitary renal cell carcinoma metastases occurring subsequent to initial curative nephrectomy: an institutional review, Ann Surg Oncol, 1, 345, 10.1007/BF02303572

Piltz, 2002, Long-term results after pulmonary resection of renal cell carcinoma metastases, Ann Thorac Surg, 73, 1082, 10.1016/S0003-4975(01)03602-5

Cerfolio, 1994, Pulmonary resection of metastatic renal cell carcinoma, Thorac Surg, 57, 339, 10.1016/0003-4975(94)90994-6

Pfannschmidt, 2002, Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma, Ann Thorac Surg, 74, 1653, 10.1016/S0003-4975(02)03803-1

Tanguay, 1996, Renal cell carcinoma metastatic to the lung:potential benefit in the combination of biological therapy and surgery, J Urol, 156, 1586, 10.1016/S0022-5347(01)65454-5

Nelson, 2004, Simultaneous thoracoscopic wedge resection of a solitary lung nodule and laparoscopic partial nephrectomy for a renal mass, Urology, 64, 377, 10.1016/j.urology.2004.04.031

Shiono, 2004, Late pulmonary metastasis of renal cell carcinoma resected 25 years after nephrectomy, Jpn J Clin Oncol, 34, 46, 10.1093/jjco/hyh010

Won, 2007, Pulmonary arteriovenous fistula arising in a renal cell carcinoma lung metastasis, Clin Radiol, 62, 812, 10.1016/j.crad.2007.02.008

Kopetz, 2007, Pulmonary arteriovenous fistula in a patient with renal cell carcinoma, Eur Respir J, 29, 813, 10.1183/09031936.00077106

Jung, 2003, Treatment of osseous metastases in patients with renal cell carcinoma, Clin Orthop Relat Res, 409, 223, 10.1097/01.blo.0000059580.08469.3e

Kuruvath, 2007, Spinal metastasis from renal cell carcinoma. 31 years following nephrectomy-case report, Clin Neuropathol, 26, 176, 10.5414/NPP26176

Rasco, 2006, Integrating metastasectomy in the management of advanced urological malignancies-where are we in 2005?, J Urol, 176, 1921, 10.1016/j.juro.2006.07.003

Sundaresan, 2002, Surgery for solitary metastases of the spine: rationale and results of treatment, Spine, 27, 1802, 10.1097/00007632-200208150-00021

Alves, 2003, Hepatic resection for metastatic renal tumors: is it worthwhile?, Ann Surg Oncol, 10, 705, 10.1245/ASO.2003.07.024

Murakami, 2000, Rupture of a hepatic metastasis from renal cell carcinoma, Clin Imaging, 24, 72, 10.1016/S0899-7071(00)00173-X

Shuch, 2008, Brain metastasis from renal cell carcinoma:presentation, recurrence, and survival, Cancer, 31

Vecil, 2003, Surgical resection of metastatic intraventricular tumors, Neurosurg Clin N Am, 14, 593, 10.1016/S1042-3680(03)00056-1

Kased, 2008, Gamma knife radiosurgery for brainstem metastases:the UCSF experience, J Neurooncol, 86, 195, 10.1007/s11060-007-9458-4

Rini, 2000, Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer, J Clin Oncol, 18, 2419, 10.1200/JCO.2000.18.12.2419

Stadler, 2004, Cytotoxic chemotherapy for metastatic renal cell carcinoma, Urologe A, 43, 145, 10.1007/s00120-004-0608-4

Rosenberg, 1987, A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone, N Engl J Med, 316, 889, 10.1056/NEJM198704093161501

Law, 1995, Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma, Cancer, 76, 824, 10.1002/1097-0142(19950901)76:5<824::AID-CNCR2820760517>3.0.CO;2-N

Weiss, 1992, A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma, J Clin Oncol, 10, 275, 10.1200/JCO.1992.10.2.275

West, 1987, Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer, N Engl J Med, 316, 898, 10.1056/NEJM198704093161502

Negrier, 1998, Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renalcell carcinoma. Groupe Français d’Immunothérapie, N Engl J Med, 338, 1272, 10.1056/NEJM199804303381805

Coppin, 2005, Immunotherapy for advanced renal cell cancer, Cochrane Database Syst Rev

Negrier, 2007, Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial, Cancer, 110, 2468, 10.1002/cncr.23056

Rak, 2001, Ras regulation of vascular endothelial growth factor and angiogenesis, Methods Enzymol, 333, 267, 10.1016/S0076-6879(01)33062-8

Hilger, 2002, The Ras-Raf-MEK-ERK pathway in the treatment of cancer, Onkologie, 25, 511, 10.1159/000068621

Oka, 1995, Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma, Cancer Res, 55, 4182

Eisenmann, 2003, Mitogen-activated protein kinase pathway-dependent tumor-specific survival signaling in melanoma cells through inactivation of the proapoptotic protein bad, Cancer Res, 63, 8330

Wang, 1996, Bcl-2 targets the protein kinase Raf-1 to mitochondria, Cell, 87, 629, 10.1016/S0092-8674(00)81383-5

Hudson, 2002, Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin, Mol Cell Biol, 22, 7004, 10.1128/MCB.22.20.7004-7014.2002

Meric-Bernstam, 2004, Mammalian target of rapamycin, Semin Oncol, 31, 10, 10.1053/j.seminoncol.2004.10.013

Thomas, 2006, Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer, Nat Med, 12, 122, 10.1038/nm1337

Atkins, 2004, Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma, J Clin Oncol, 22, 909, 10.1200/JCO.2004.08.185

Hudes, 2007, Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma, N Engl J Med, 356, 2271, 10.1056/NEJMoa066838

Mendel, 2003, In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship, Clin Cancer Res, 9, 327

Motzer, 2006, Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma, J Clin Oncol, 24, 16, 10.1200/JCO.2005.02.2574

Motzer, 2006, Sunitinib in patients with metastatic renal cell carcinoma, JAMA, 295, 2516, 10.1001/jama.295.21.2516

Rini, 2007, Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib, J Natl Cancer Inst, 99, 81, 10.1093/jnci/djk008

Wilhelm, 2004, BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/ MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis, Cancer Res, 64, 7099, 10.1158/0008-5472.CAN-04-1443

Ratain, 2006, Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma, J Clin Oncol, 24, 2505, 10.1200/JCO.2005.03.6723

Presta, 1997, Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders, Cancer Res, 57, 4593

Yang, 2003, A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer, N Engl J Med, 349, 427, 10.1056/NEJMoa021491

Tamaskar, 2008, Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy, J Urol, 179, 81, 10.1016/j.juro.2007.08.127

Bergers, 2008, Modes of resistance to anti-angiogenic therapy, Nat Rev Cancer, 8, 592, 10.1038/nrc2442

Casanovas, 2005, Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in latestage pancreatic islet tumors, Cancer Cell, 8, 299, 10.1016/j.ccr.2005.09.005

Rubenstein, 2000, Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption, Neoplasia, 2, 306, 10.1038/sj.neo.7900102

Jain, 2001, Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy, Nat Med, 7, 987, 10.1038/nm0901-987

Flanigan, 2001, Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer, N Engl J Med, 345, 1655, 10.1056/NEJMoa003013

Mickisch, 2001, Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma:a randomized trial, Lancet, 358, 966, 10.1016/S0140-6736(01)06103-7

Flanigan, 2004, Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis, J Urol, 171, 1071, 10.1097/01.ju.0000110610.61545.ae

Pantuck, 2007, Cytoreductive nephrectomy for metastatic renal cell carcinoma: is it still imperative in the era of targeted therapy?, Clin Cancer Res, 13, 693s, 10.1158/1078-0432.CCR-06-1916

Rini, 2007, The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy, J Urol, 177, 1978, 10.1016/j.juro.2007.01.136

Thông tin
Thông tin xuất bản

Progrès en Urologie

Tập 18

S298-S308

Thông tin tác giả